NCT06623487 The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
| NCT ID | NCT06623487 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Carcinoma, Non-Small-Cell Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-07-19 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-07-19 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neoadjuvant immunotherapy can significantly improve the pathological complete response (pCR) and major pathological response (MPR) rates in resectable stage III non-small cell lung cancer (NSCLC), and extend the event-free survival (EFS). However, the current means for evaluating its efficacy are limited. This study aims to utilize the convenient and non-invasive 68Ga-grazytracer PET imaging to detect the aggregation of CD8+ T cells in target lesions after neoadjuvant immunotherapy for stage III NSCLC, and to assess its value in efficacy monitoring, providing valuable information for clinical treatment decisions.
Eligibility Criteria
Inclusion Criteria: 1. Patients with stage III NSCLC, after assessment according to clinical guidelines, require neoadjuvant immunotherapy; 2. Fully-informed written consent obtained from patients; 3. Patient ability to comply with protocol requirements; 4. Age 18-75 years; 5. Life expectancy of at least 6 months. Exclusion Criteria: 1. Patients with serious diseases that the investigator deems unsuitable for participation in the clinical study. Such as severe cardiopulmonary insufficiency, severe bone marrow suppression, severe hepatic or renal insufficiency, etc; 2. Intestinal perforation, complete intestinal obstruction; 3. Patients with uncontrolled diabetes mellitus or a fasting blood glucose value of ≥11 mmol/L on the day of the test; 4. Pregnant women and women who are potentially pregnant, as well as nursing mothers; 5. Patients with poor compliance.
Frequently Asked Questions
Who can join the NCT06623487 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Carcinoma, Non-Small-Cell Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06623487 currently recruiting?
Yes, NCT06623487 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ruijin Hospital to inquire about joining.
Where is the NCT06623487 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06623487 clinical trial?
NCT06623487 is sponsored by Ruijin Hospital. The trial plans to enroll 30 participants.